IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study
IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study
复制标题
DOI：
10.1016/j.cca.2020.04.026
复制
发表时间：
2020-08-01
影响因子：
5
通讯作者：
Plebani, Mario
中科院分区：
文献类型：
--
作者：
Padoan, Andrea;Sciacovelli, Laura;Plebani, Mario
血清学抗体检测的验证研究必须针对临床、流行病学和公共卫生目标进行适当设计，例如疑似 COVID-19 病例的确认、感染后血清转化的证明以及流行病学监测。我们评估了确诊 (rRT-PCR) 感染的 COVID-19 患者中 IgM、IgA 和 IgG SARS-CoV-2 抗体的动力学。我们发现 IgA 反应出现并生长较早，在第 3 周达到峰值，并且比 IgM 反应更强、更持久。需要对病毒特异性抗体的功能及其随时间的保护效力进行进一步的纵向研究。
Validation studies of serological antibody tests must be properly designed for clinical, epidemiological and Public Health objectives such as confirmation of suspected COVID-19 cases, certification of seroconversion after infection, and epidemiological surveillance. We evaluated the kinetics of IgM, IgA and IgG SARS-CoV-2 antibodies in COVID-19 patients with confirmed (rRT-PCR) infection. We found that the IgA response appears and grows early, peaks at week 3, and it is stronger and more persistent than the IgM response. Further longitudinal investigations of virus-specific antibodies functions and of their protective efficacy over time are needed.